140 related articles for article (PubMed ID: 37463243)
1. Exploiting an epigenetic switch in adrenal cancer.
Ferrarelli LK
Sci Signal; 2023 Jul; 16(794):eadj7203. PubMed ID: 37463243
[TBL] [Abstract][Full Text] [Related]
2. EZH2 is overexpressed in adrenocortical carcinoma and is associated with disease progression.
Drelon C; Berthon A; Mathieu M; Ragazzon B; Kuick R; Tabbal H; Septier A; Rodriguez S; Batisse-Lignier M; Sahut-Barnola I; Dumontet T; Pointud JC; Lefrançois-Martinez AM; Baron S; Giordano TJ; Bertherat J; Martinez A; Val P
Hum Mol Genet; 2016 Jul; 25(13):2789-2800. PubMed ID: 27149985
[TBL] [Abstract][Full Text] [Related]
3. Enhancer of zeste homolog 2 (EZH2) inhibitors.
Gulati N; Béguelin W; Giulino-Roth L
Leuk Lymphoma; 2018 Jul; 59(7):1574-1585. PubMed ID: 29473431
[TBL] [Abstract][Full Text] [Related]
4. Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target.
Wen Y; Cai J; Hou Y; Huang Z; Wang Z
Oncotarget; 2017 Jun; 8(23):37974-37990. PubMed ID: 28415635
[TBL] [Abstract][Full Text] [Related]
5. EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy.
Sun S; Yu F; Xu D; Zheng H; Li M
Biochim Biophys Acta Rev Cancer; 2022 Mar; 1877(2):188700. PubMed ID: 35217116
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
[TBL] [Abstract][Full Text] [Related]
7. EZH2 as an Epigenetic Regulator of Cardiovascular Development and Diseases.
Yuan JL; Yin CY; Li YZ; Song S; Fang GJ; Wang QS
J Cardiovasc Pharmacol; 2021 Aug; 78(2):192-201. PubMed ID: 34029268
[TBL] [Abstract][Full Text] [Related]
8. Potential of enhancer of zeste homolog 2 inhibitors for the treatment of SWI/SNF mutant cancers and tumor microenvironment modulation.
Pyziak K; Sroka-Porada A; Rzymski T; Dulak J; Łoboda A
Drug Dev Res; 2021 Sep; 82(6):730-753. PubMed ID: 33565092
[TBL] [Abstract][Full Text] [Related]
9. EZH2 cooperates with E2F1 to stimulate expression of genes involved in adrenocortical carcinoma aggressiveness.
Tabbal H; Septier A; Mathieu M; Drelon C; Rodriguez S; Djari C; Batisse-Lignier M; Tauveron I; Pointud JC; Sahut-Barnola I; Ragazzon B; Assié G; Bertherat J; Lefrançois-Martinez AM; Martinez A; Val P
Br J Cancer; 2019 Aug; 121(5):384-394. PubMed ID: 31363169
[TBL] [Abstract][Full Text] [Related]
10. SETting Up for Epigenetic Regulation of Advanced Prostate Cancer.
Thienger P; Rubin MA
Cancer Cell; 2020 Sep; 38(3):309-311. PubMed ID: 32931739
[TBL] [Abstract][Full Text] [Related]
11. EZH2-mediated Epigenetic Silencing of miR-29/miR-30 targets LOXL4 and contributes to Tumorigenesis, Metastasis, and Immune Microenvironment Remodeling in Breast Cancer.
Yin H; Wang Y; Wu Y; Zhang X; Zhang X; Liu J; Wang T; Fan J; Sun J; Yang A; Zhang R
Theranostics; 2020; 10(19):8494-8512. PubMed ID: 32754259
[TBL] [Abstract][Full Text] [Related]
12. EZH2 as a mediator of treatment resistance in melanoma.
Tiffen JC; Gallagher SJ; Tseng HY; Filipp FV; Fazekas de St. Groth B; Hersey P
Pigment Cell Melanoma Res; 2016 Sep; 29(5):500-7. PubMed ID: 27063195
[TBL] [Abstract][Full Text] [Related]
13. Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo.
Wen S; Wang J; Liu P; Li Y; Lu W; Hu Y; Liu J; He Z; Huang P
Cancer Lett; 2018 Jan; 413():35-45. PubMed ID: 29069576
[TBL] [Abstract][Full Text] [Related]
14. Functional and therapeutic significance of EZH2 in urological cancers.
Liu X; Wu Q; Li L
Oncotarget; 2017 Jun; 8(23):38044-38055. PubMed ID: 28410242
[TBL] [Abstract][Full Text] [Related]
15. Structural assembly of Polycomb group protein and Insight of EZH2 in cancer progression: A review.
Gautam N; Kaur M; Kaur S
J Cancer Res Ther; 2021; 17(2):311-326. PubMed ID: 33063698
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic Therapy for Epithelioid Sarcoma.
Rothbart SB; Baylin SB
Cell; 2020 Apr; 181(2):211. PubMed ID: 32302562
[TBL] [Abstract][Full Text] [Related]
17. EZH2 as a Regulator of CD8+ T Cell Fate and Function.
Stairiker CJ; Thomas GD; Salek-Ardakani S
Front Immunol; 2020; 11():593203. PubMed ID: 33117406
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the histone lysine methyltransferase EZH2 for the treatment of cancer.
Verma SK
Curr Top Med Chem; 2015; 15(8):714-9. PubMed ID: 25732793
[TBL] [Abstract][Full Text] [Related]
19. Epigenetics in lymphocyte and lymphoma: EZH2 as an easy-to-access therapeutic target?
Kato K
Int J Hematol; 2022 Dec; 116(6):819-820. PubMed ID: 36273114
[No Abstract] [Full Text] [Related]
20. Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer.
Shi B; Behrens C; Vaghani V; Riquelme EM; Rodriguez-Canales J; Kadara H; Lin H; Lee J; Liu H; Wistuba I; Simon G
Cancer Med; 2019 Oct; 8(14):6383-6392. PubMed ID: 31456359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
